MedTech logo
 
 
 
 
 
 
temp_image_2

t: 0161 820 8440

e:  

News

Phagenesis newest client for MedTECH Centre

01 August 2010

Phagenesis have taken up residence in the MTC, as their operational HQ. The company has just closed a very successful funding round and have an exciting schedule of development ahead. Phagenesis Limited, a leader in technology for the treatment of stroke patients, has appointed Henry Hyde-Thomson as Chairman and Daniel Green as Chief Executive Officer.
 

Both bring a wealth of experience in growing young companies to the University of Manchester spinout. They will lead Phagenesis in the development of a new class of treatments for stroke victims suffering from dysphagia, a common condition that prevents or impairs the safe swallowing of food and drink.
 

Phagenesis’ technology is a device that delivers electrical pulses to the throat region that can “awaken” the brain to help restore swallowing function. At least 50% of stroke victims have impaired swallowing.

Phagenesis

Phagenesis

back to news listing

Supported by:


Central Manchester University Hospitals logoManchester Science Parks logoTrusTECH logo